Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Therapeutics Development Initiative, 2010
    HE3286 as Treatment for Parkinson's Disease

    Objective/Rationale
    Dehydroepiandrosterone (DHEA), a common neutraceutical and potent neuro-steroid has been suggested as a neuroprotective treatment for Parkinson’s disease (PD). However, DHEA is...

  • Therapeutics Development Initiative, 2010
    A Novel Prodrug of Acamprosate for Treatment of L-DOPA-Induced Dyskinesias

    Objective/Rationale: 
    The primary objective of this proposal is to determine if a prodrug of acamprosate could inhibit L-DOPA induced dyskinesias (LID).  Functional interactions between the dopamine...

  • Alpha-Synuclein Therapeutics, 2010
    Targeting Alpha-Synuclein Dephosphorylation via PP2A Activation as a Novel PD Therapeutic

    Objective/Rationale:
    Alpha-synuclein is a prime target for Parkinson’s disease (PD). Excessive phosphorylation of alpha-synuclein can contribute to pathology, thus mechanisms to decrease its...

  • Alpha-Synuclein Therapeutics, 2010
    AFFITOPE based immunotherapeutic strategies for Parkinson´s disease

    Objective/Rationale: 
    Parkinson’s disease (PD) is characterized by the formation of abnormal alpha-synuclein accumulations, so called Lewy bodies, in the nervous system. Alpha-synuclein is currently...

  • Alpha-Synuclein Therapeutics, 2010
    A Pre-Clinical Study in a PD-like Transgenic Pre-Clinical Model of a Novel Isoindole Compound that Selectively Blocks Alpha-Synuclein Oligomerization

    Objective/Rationale: 
    The damage to neuronal cells and connections in Parkinson’s disease is associated with the abnormal accumulation of a neuronal protein denominated alpha-synuclein. We have...

  • Alpha-Synuclein Therapeutics, 2010
    Morphology Specific Anti-Synuclein Nanobodies as Therapeutics for PD

    Objective/Rationale: 
    Aggregation and deposition of the protein, a-synuclein (a-syn), has been strongly correlated with PD and other related neurodegenerative disorders. The a-syn protein occurs in a...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.